What is your preferred approach to PMRT with inflammatory breast cancer with adverse risk features?

Our approach is same of 50 Gy in 25 fractions to CW and Regional node with higher boost dose of 10-16 Gy

Inflammatory breast cancer is most commonly triple negative or HER2 amplified disease. Patients with significant residual disease after preoperative chemotherapy have extremely high rates of relapse. Participation on SWOG1706 (NCT03598257, @Dr. First Last PI), a phase II randomized trial of olaparib...